BBIO

76.0302.75%
TT

Thomas Trimarchi

CFO & President

Dr. Thomas Trimarchi, Ph.D., is President of BridgeBio Pharma, Inc. from July 23, 2024 and served as its Chief Operating Officer from July 23, 2024 until March 2025 and serves as its Chief Financial Officer since March 2025. Dr. Trimarchi was Chief Product Officer of BridgeBio Pharma, Inc. from February 2021 until July 23, 2024. He joined BridgeBio Pharma, Inc. in 2018. Dr. Trimarchi is responsible for driving operational excellence, strategic planning and overall business success at BridgeBio. He is to lead cross-functional activities to develop a centralized operation across the late-stage pipeline prioritizing efficiency, rigor and scale. Dr. Trimarchi served as Chief Regulatory Affairs Officer at BridgeBio Pharma, Inc. since December 2021. Dr. Trimarchi served as Research Analyst at Goldman Sachs Group Inc., Research Division since 2015 until 2017. He served as Senior Vice President of Product at BridgeBio Pharma, Inc. He covered the biotechnology sector. Dr. Trimarchi has also served as a member of the board of directors of subsidiary, ML Bio Solutions, Inc., a BridgeBio affiliate, since November 2021. Prior to joining the Company, Dr. Trimarchi worked in corporate strategy at Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) from March 2017 to April 2018 and as an equity analyst in the Global Investment Research division at The Goldman Sachs Group (NYSE: GS) from August 2015 to March 2017. Dr. Trimarchi received his Ph.D. in Molecular Oncology and Immunology, Cell and Molecular Biology from New York University Grossman School of Medicine and a B.S. in Biology from the University of Vermont.

Positions